Targeting receptor proteins, such as ligand-gated ion channels and G protein-coupled receptors, has directly enabled the discovery of most drugs developed to modulate receptor signalling. However, as the search for novel and improved drugs continues, an innovative approach — targeting receptor complexes — is emerging. Receptor complexes are composed of core receptor proteins and receptor-associated proteins, which have profound effects on the overall receptor structure, function and localization. Hence, targeting key protein–protein interactions within receptor complexes provides an opportunity to develop more selective drugs with fewer side effects. In this Review, we discuss our current understanding of ligand-gated ion channel and G protein-coupled receptor complexes and discuss strategies for their pharmacological modulation. Although such strategies are still in preclinical development for most receptor complexes, they exemplify how receptor complexes can be drugged, and lay the groundwork for this nascent area of research.
Subscribe to Journal
Get full journal access for 1 year
only $21.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Santos, R. et al. A comprehensive map of molecular drug targets. Nat. Rev. Drug Discov. 16, 19–34 (2017).
Maher, M. P., Matta, J. A., Gu, S., Seierstad, M. & Bredt, D. S. Getting a handle on neuropharmacology by targeting receptor-associated proteins. Neuron 96, 989–1001 (2017).
Huttlin, E. L. et al. Architecture of the human interactome defines protein communities and disease networks. Nature 545, 505–509 (2017).
Rual, J. F. et al. Towards a proteome-scale map of the human protein-protein interaction network. Nature 437, 1173–1178 (2005).
Uhlen, M. et al. Proteomics. Tissue-based map of the human proteome. Science 347, 1260419 (2015).
Hein, M. Y. et al. A human interactome in three quantitative dimensions organized by stoichiometries and abundances. Cell 163, 712–723 (2015).
Huttlin, E. L. et al. The BioPlex network: a systematic exploration of the human interactome. Cell 162, 425–440 (2015).
Pin, J. P. & Bettler, B. Organization and functions of mGlu and GABAB receptor complexes. Nature 540, 60–68 (2016).
Osten, P. & Stern-Bach, Y. Learning from stargazin: the mouse, the phenotype and the unexpected. Curr. Opin. Neurobiol. 16, 275–280 (2006).
Isom, L. L., De Jongh, K. S. & Catterall, W. A. Auxiliary subunits of voltage-gated ion channels. Neuron 12, 1183–1194 (1994).
Jackson, A. C. & Nicoll, R. A. The expanding social network of ionotropic glutamate receptors: TARPs and other transmembrane auxiliary subunits. Neuron 70, 178–199 (2011).
Yan, D. & Tomita, S. Defined criteria for auxiliary subunits of glutamate receptors. J. Physiol. 590, 21–31 (2012).
Pfeiffer, F., Graham, D. & Betz, H. Purification by affinity chromatography of the glycine receptor of rat spinal cord. J. Biol. Chem. 257, 9389–9393 (1982).
Tretter, V. et al. The clustering of GABAA receptor subtypes at inhibitory synapses is facilitated via the direct binding of receptor alpha 2 subunits to gephyrin. J. Neurosci. 28, 1356–1365 (2008).
Maric, H. M. et al. Gephyrin-binding peptides visualize postsynaptic sites and modulate neurotransmission. Nat. Chem. Biol. 13, 153–160 (2017).
Maric, H. M. et al. Molecular basis of the alternative recruitment of GABAA versus glycine receptors through gephyrin. Nat. Commun. 5, 5767 (2014).
Li, J. et al. Artemisinins target GABAA receptor signaling and impair alpha cell identity. Cell 168, 86–100 (2017).
Han, W. et al. Shisa7 is a GABAA receptor auxiliary subunit controlling benzodiazepine actions. Science 366, 246–250 (2019).
Letts, V. A. et al. The mouse stargazer gene encodes a neuronal Ca2+-channel gamma subunit. Nat. Genet. 19, 340–347 (1998).
Chen, L. et al. Stargazin regulates synaptic targeting of AMPA receptors by two distinct mechanisms. Nature 408, 936–943 (2000).
Hashimoto, K. et al. Impairment of AMPA receptor function in cerebellar granule cells of ataxic mutant mouse stargazer. J. Neurosci. 19, 6027–6036 (1999).
Tomita, S. et al. Stargazin modulates AMPA receptor gating and trafficking by distinct domains. Nature 435, 1052–1058 (2005).
Tomita, S. et al. Functional studies and distribution define a family of transmembrane AMPA receptor regulatory proteins. J. Cell Biol. 161, 805–816 (2003).
Twomey, E. C., Yelshanskaya, M. V., Grassucci, R. A., Frank, J. & Sobolevsky, A. I. Elucidation of AMPA receptor-stargazin complexes by cryo-electron microscopy. Science 353, 83–86 (2016).
Zhao, Y., Chen, S., Yoshioka, C., Baconguis, I. & Gouaux, E. Architecture of fully occupied GluA2 AMPA receptor-TARP complex elucidated by cryo-EM. Nature 536, 108–111 (2016).
Herguedas, B. et al. Architecture of the heteromeric GluA1/2 AMPA receptor in complex with the auxiliary subunit TARP gamma8. Science 364, eaav9011 (2019).
Twomey, E. C., Yelshanskaya, M. V., Grassucci, R. A., Frank, J. & Sobolevsky, A. I. Structural bases of desensitization in AMPA receptor-auxiliary subunit complexes. Neuron 94, 569–580.e565 (2017).
Twomey, E. C., Yelshanskaya, M. V., Grassucci, R. A., Frank, J. & Sobolevsky, A. I. Channel opening and gating mechanism in AMPA-subtype glutamate receptors. Nature 549, 60–65 (2017).
Schwenk, J. et al. Functional proteomics identify cornichon proteins as auxiliary subunits of AMPA receptors. Science 323, 1313–1319 (2009).
Schwenk, J. et al. Regional diversity and developmental dynamics of the AMPA-receptor proteome in the mammalian brain. Neuron 84, 41–54 (2014).
Schwenk, J. et al. High-resolution proteomics unravel architecture and molecular diversity of native AMPA receptor complexes. Neuron 74, 621–633 (2012). Using high-resolution proteomics, this study showcases the complexity of AMPAR complexes by identifying 21 receptor-associated proteins.
Frank, R. A. et al. NMDA receptors are selectively partitioned into complexes and supercomplexes during synapse maturation. Nat. Commun. 7, 11264 (2016).
Lei, N., Mellem, J. E., Brockie, P. J., Madsen, D. M. & Maricq, A. V. NRAP-1 is a presynaptically released NMDA receptor auxiliary protein that modifies synaptic strength. Neuron 96, 1303–1316 (2017).
Jackson, D. S., Ramachandrappa, S., Clark, A. J. & Chan, L. F. Melanocortin receptor accessory proteins in adrenal disease and obesity. Front. Neurosci. 9, 213 (2015).
Xu, A. et al. Identification of novel putative membrane proteins selectively expressed during adipose conversion of 3T3-L1 cells. Biochemical Biophysical Res. Commun. 293, 1161–1167 (2002).
Metherell, L. A. et al. Mutations in MRAP, encoding a new interacting partner of the ACTH receptor, cause familial glucocorticoid deficiency type 2. Nat. Genet. 37, 166–170 (2005).
Chan, L. F. et al. MRAP and MRAP2 are bidirectional regulators of the melanocortin receptor family. Proc. Natl Acad. Sci. USA 106, 6146–6151 (2009).
Asai, M. et al. Loss of function of the melanocortin 2 receptor accessory protein 2 is associated with mammalian obesity. Science 341, 275–278 (2013).
Sebag, J. A., Zhang, C., Hinkle, P. M., Bradshaw, A. M. & Cone, R. D. Developmental control of the melanocortin-4 receptor by MRAP2 proteins in zebrafish. Science 341, 278–281 (2013).
Schwenk, J. et al. Native GABA(B) receptors are heteromultimers with a family of auxiliary subunits. Nature 465, 231–235 (2010). This study demonstrates that KCTD proteins are auxiliary GABAB receptor subunits that confer the kinetic properties of native receptors to the recombinant receptors.
Schwenk, J. et al. Modular composition and dynamics of native GABAB receptors identified by high-resolution proteomics. Nat. Neurosci. 19, 233–242 (2016).
Belliotti, T. R. et al. Structure-activity relationships of pregabalin and analogues that target the alpha(2)-delta protein. J. Med. Chem. 48, 2294–2307 (2005).
Gee, N. S. et al. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J. Biol. Chem. 271, 5768–5776 (1996).
Lee, K. P. K., Chen, J. & MacKinnon, R. Molecular structure of human KATP in complex with ATP and ADP. eLife 6, e32481 (2017).
Wu, J. X. et al. Ligand binding and conformational changes of SUR1 subunit in pancreatic ATP-sensitive potassium channels. Protein Cell 9, 553–567 (2018).
Henquin, J. C. The fiftieth anniversary of hypoglycaemic sulphonamides. How did the mother compound work? Diabetologia 35, 907–912 (1992).
Aguilar-Bryan, L. et al. Cloning of the beta cell high-affinity sulfonylurea receptor: a regulator of insulin secretion. Science 268, 423–426 (1995).
Inagaki, N. et al. Reconstitution of IKATP: an inward rectifier subunit plus the sulfonylurea receptor. Science 270, 1166–1170 (1995).
Martin, G. M., Kandasamy, B., DiMaio, F., Yoshioka, C. & Shyng, S. L. Anti-diabetic drug binding site in a mammalian KATP channel revealed by cryo-EM. eLife 6, e31054 (2017).
Mehta, R. I. et al. Sur1-Trpm4 cation channel expression in human cerebral infarcts. J. Neuropathol. Exp. Neurol. 74, 835–849 (2015).
Sala-Rabanal, M., Wang, S. & Nichols, C. G. On potential interactions between non-selective cation channel TRPM4 and sulfonylurea receptor SUR1. J. Biol. Chem. 287, 8746–8756 (2012).
Simard, J. M. et al. Newly expressed SUR1-regulated NCCa-ATP channel mediates cerebral edema after ischemic stroke. Nat. Med. 12, 433–440 (2006).
King, Z. A., Sheth, K. N., Kimberly, W. T. & Simard, J. M. Profile of intravenous glyburide for the prevention of cerebral edema following large hemispheric infarction: evidence to date. Drug Des. Devel. Ther. 12, 2539–2552 (2018).
Sheth, K. N. et al. Human data supporting glyburide in ischemic stroke. Acta Neurochir. Suppl. 121, 13–18 (2016).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02864953 (2020).
Granier, S. et al. Structure of the delta-opioid receptor bound to naltrindole. Nature 485, 400–404 (2012).
Manglik, A. et al. Crystal structure of the micro-opioid receptor bound to a morphinan antagonist. Nature 485, 321–326 (2012).
Wu, H. et al. Structure of the human kappa-opioid receptor in complex with JDTic. Nature 485, 327–332 (2012).
Foster, D. J. & Conn, P. J. Allosteric modulation of GPCRs: new insights and potential utility for treatment of schizophrenia and other CNS disorders. Neuron 94, 431–446 (2017).
Scott, D. E., Bayly, A. R., Abell, C. & Skidmore, J. Small molecules, big targets: drug discovery faces the protein-protein interaction challenge. Nat. Rev. Drug Discov. 15, 533–550 (2016).
Ran, X. & Gestwicki, J. E. Inhibitors of protein-protein interactions (PPIs): an analysis of scaffold choices and buried surface area. Curr. Opin. Chem. Biol. 44, 75–86 (2018).
Neves, V., Aires-da-Silva, F., Corte-Real, S. & Castanho, M. A. R. B. Antibody approaches to treat brain diseases. Trends Biotechnol. 34, 36–48 (2016).
Hutchings, C. J., Koglin, M., Olson, W. C. & Marshall, F. H. Opportunities for therapeutic antibodies directed at G-protein-coupled receptors. Nat. Rev. Drug Discov. 16, 787–810 (2017).
Wulff, H., Christophersen, P., Colussi, P., Chandy, K. G. & Yarov-Yarovoy, V. Antibodies and venom peptides: new modalities for ion channels. Nat. Rev. Drug Discov. 18, 339–357 (2019).
Hutchings, C. J., Colussi, P. & Clark, T. G. Ion channels as therapeutic antibody targets. MAbs 11, 265–296 (2019).
Edvinsson, L., Haanes, K. A., Warfvinge, K. & Krause, D. N. CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat. Rev. Neurol. 14, 338–350 (2018).
Köhler, G. & Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495–497 (1975).
Frenzel, A., Schirrmann, T. & Hust, M. Phage display-derived human antibodies in clinical development and therapy. MAbs 8, 1177–1194 (2016).
Smith, G. P. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228, 1315–1317 (1985).
Bagal, S. K. et al. Ion channels as therapeutic targets: a drug discovery perspective. J. Med. Chem. 56, 593–624 (2013).
Zhang, R. & Xie, X. Tools for GPCR drug discovery. Acta Pharmacol. Sin. 33, 372–384 (2012).
Macarron, R. et al. Impact of high-throughput screening in biomedical research. Nat. Rev. Drug Discov. 10, 188–195 (2011).
Gardinier, K. M. et al. Discovery of the first α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist dependent upon transmembrane AMPA receptor regulatory protein (TARP) γ-8. J. Med. Chem. 59, 4753–4768 (2016). Together with Kato et al. (2016), this reports the first AMPAR–TARPγ8-selective small-molecule antagonist, which mitigates side effects associated with global AMPAR inhibition.
Kato, A. S. et al. Forebrain-selective AMPA-receptor antagonism guided by TARP gamma-8 as an antiepileptic mechanism. Nat. Med. 22, 1496–1501 (2016). Together with Gardiniere et al. (2016), this reports the first AMPAR–TARPγ8-selective small-molecule antagonist.
Maher, M. P. et al. Discovery and characterization of AMPA receptor modulators selective for TARP-gamma8. J. Pharmacol. Exp. Ther. 357, 394–414 (2016).
Ottl, J., Leder, L., Schaefer, J. V. & Dumelin, C. E. Encoded library technologies as integrated lead finding platforms for drug discovery. Molecules 24, 1629 (2019).
Ahn, S. et al. Allosteric “beta-blocker” isolated from a DNA-encoded small molecule library. Proc. Natl Acad. Sci. USA 114, 1708–1713 (2017).
Schapira, M., Calabrese, M. F., Bullock, A. N. & Crews, C. M. Targeted protein degradation: expanding the toolbox. Nat. Rev. Drug Discov. 18, 949–963 (2019).
Aarts, M. et al. Treatment of ischemic brain damage by perturbing NMDA receptor- PSD-95 protein interactions. Science 298, 846–850 (2002). This article describes the development of the first PSD95 inhibitor NA-1 and how it protects against ischaemic damage in rats.
Bach, A. et al. A high-affinity, dimeric inhibitor of PSD-95 bivalently interacts with PDZ1-2 and protects against ischemic brain damage. Proc. Natl Acad. Sci. USA 109, 3317–3322 (2012).
Fosgerau, K. & Hoffmann, T. Peptide therapeutics: current status and future directions. Drug Discov. Today 20, 122–128 (2015).
Henninot, A., Collins, J. C. & Nuss, J. M. The current state of peptide drug discovery: back to the future? J. Med. Chem. 61, 1382–1414 (2018).
Lau, Y. H., de Andrade, P., Wu, Y. & Spring, D. R. Peptide stapling techniques based on different macrocyclisation chemistries. Chem. Soc. Rev. 44, 91–102 (2015).
Frank, R. Spot-synthesis: an easy technique for the positionally addressable, parallel chemical synthesis on a membrane support. Tetrahedron 48, 9217–9232 (1992).
Galan, A. et al. Library-based display technologies: where do we stand? Mol. Biosyst. 12, 2342–2358 (2016).
Huang, Y., Wiedmann, M. M. & Suga, H. RNA display methods for the discovery of bioactive macrocycles. Chem. Rev. 119, 10360–10391 (2019).
Rogers, J. M., Passioura, T. & Suga, H. Nonproteinogenic deep mutational scanning of linear and cyclic peptides. Proc. Natl. Acad. Sci. USA 115, 10959–10964 (2018).
Passioura, T. & Suga, H. A RaPID way to discover nonstandard macrocyclic peptide modulators of drug targets. Chem. Commun. 53, 1931–1940 (2017).
Weidmann, J. & Craik, D. J. Discovery, structure, function, and applications of cyclotides: circular proteins from plants. J. Exp. Bot. 67, 4801–4812 (2016).
Green, M. & Loewenstein, P. M. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell 55, 1179–1188 (1988).
Frankel, A. D. & Pabo, C. O. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 55, 1189–1193 (1988).
El-Andaloussi, S., Jarver, P., Johansson, H. J. & Langel, U. Cargo-dependent cytotoxicity and delivery efficacy of cell-penetrating peptides: a comparative study. Biochem. J. 407, 285–292 (2007).
Qian, Z. et al. Discovery and mechanism of highly efficient cyclic cell-penetrating peptides. Biochemistry 55, 2601–2612 (2016).
Peraro, L. & Kritzer, J. A. Emerging methods and design principles for cell-penetrant peptides. Angew. Chem. Int. Ed. 57, 11868–11881 (2018).
Keating, G. M. Netupitant/palonosetron: a review in the prevention of chemotherapy-induced nausea and vomiting. Drugs 75, 2131–2141 (2015).
Smart, T. G. & Stephenson, F. A. A half century of gamma-aminobutyric acid. Brain Neurosci. Adv. 3, 2398212819858249 (2019).
Jordan, C. J. & Xi, Z. X. Discovery and development of varenicline for smoking cessation. Expert Opin. Drug Discov. 13, 671–683 (2018).
Kraus, C. et al. The influence of ketamine on drug discovery in depression. Drug Discov. Today 24, 2033–243 (2019).
Yang, Y. et al. Ketamine blocks bursting in the lateral habenula to rapidly relieve depression. Nature 554, 317–322 (2018).
Liriano, F., Hatten, C. & Schwartz, T. L. Ketamine as treatment for post-traumatic stress disorder: a review. Drugs Context 8, 212305 (2019).
Preskorn, S. H. et al. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J. Clin. Psychopharmacol. 28, 631–637 (2008).
Ogden, K. K. & Traynelis, S. F. New advances in NMDA receptor pharmacology. Trends Pharmacol. Sci. 32, 726–733 (2011).
Olney, J. W., Labruyere, J. & Price, M. T. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 244, 1360–1362 (1989).
Addy, C. et al. Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson’s disease. J. Clin. Pharmacol. 49, 856–864 (2009).
Kornau, H. C., Schenker, L. T., Kennedy, M. B. & Seeburg, P. H. Domain interaction between NMDA receptor subunits and the postsynaptic density protein PSD-95. Science 269, 1737–1740 (1995).
Kim, E., Niethammer, M., Rothschild, A., Jan, Y. N. & Sheng, M. Clustering of Shaker-type K+ channels by interaction with a family of membrane-associated guanylate kinases. Nature 378, 85–88 (1995).
Zeng, M. et al. Reconstituted postsynaptic density as a molecular platform for understanding synapse formation and plasticity. Cell 174, 1172–1187 (2018).
Brenman, J. E. et al. Interaction of nitric oxide synthase with the postsynaptic density protein PSD-95 and α1-syntrophin mediated by PDZ domains. Cell 84, 757–767 (1996).
Christopherson, K. S., Hillier, B. J., Lim, W. A. & Bredt, D. S. PSD-95 assembles a ternary complex with the N-methyl-D-aspartic acid receptor and a bivalent neuronal NO synthase PDZ domain. J. Biol. Chem. 274, 27467–27473 (1999).
Sattler, R. et al. Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein. Science 284, 1845–1848 (1999).
Luo, C. X. et al. Interaction of nNOS with PSD-95 negatively controls regenerative repair after stroke. J. Neurosci. 34, 13535–13548 (2014).
Boissel, J. P., Bros, M., Schrock, A., Godtel-Armbrust, U. & Forstermann, U. Cyclic AMP-mediated upregulation of the expression of neuronal NO synthase in human A673 neuroepithelioma cells results in a decrease in the level of bioactive NO production: analysis of the signaling mechanisms that are involved. Biochemistry 43, 7197–7206 (2004).
Pou, S., Keaton, L., Surichamorn, W. & Rosen, G. M. Mechanism of superoxide generation by neuronal nitric-oxide synthase. J. Biol. Chem. 274, 9573–9580 (1999).
Schulz, J. B., Matthews, R. T., Klockgether, T., Dichgans, J. & Beal, M. F. The role of mitochondrial dysfunction and neuronal nitric oxide in animal models of neurodegenerative diseases. Mol. Cell. Biochem. 174, 193–197 (1997).
Grillo-Bosch, D., Choquet, D. & Sainlos, M. Inhibition of PDZ domain-mediated interactions. Drug Discov. Today Technol. 10, e531–e540 (2013).
Lapchak, P. A. & Zhang, J. H. Neuroprotective Therapy for Stroke and Ischemic Disease. 157-184 (Springer International Publishing, 2017).
Ballarin, B. & Tymianski, M. Discovery and development of NA-1 for the treatment of acute ischemic stroke. Acta Pharmacol. Sin. 39, 661–668 (2018).
Florio, S. K. et al. Disruption of nNOS-PSD95 protein-protein interaction inhibits acute thermal hyperalgesia and chronic mechanical allodynia in rodents. Br. J. Pharmacol. 158, 494–506 (2009).
Zhou, L. et al. Treatment of cerebral ischemia by disrupting ischemia-induced interaction of nNOS with PSD-95. Nat. Med. 16, 1439–1443 (2010).
Bach, A. et al. Biochemical investigations of the mechanism of action of small molecules ZL006 and IC87201 as potential inhibitors of the nNOS-PDZ/PSD-95-PDZ interactions. Sci. Rep. 5, 12157 (2015).
Cui, H. et al. PDZ protein interactions underlying NMDA receptor-mediated excitotoxicity and neuroprotection by PSD-95 inhibitors. J. Neurosci. 27, 9901–9915 (2007).
Cook, D. J., Teves, L. & Tymianski, M. A translational paradigm for the preclinical evaluation of the stroke neuroprotectant Tat-NR2B9c in gyrencephalic nonhuman primates. Sci. Transl Med. 4, 154ra133 (2012).
Cook, D. J., Teves, L. & Tymianski, M. Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brain. Nature 483, 213–217 (2012).
Hill, M. D. et al. Safety and efficacy of NA-1 in patients with iatrogenic stroke after endovascular aneurysm repair (ENACT): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 11, 942–950 (2012).
US National Library of Medicine ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02930018 (2020).
Hill, M. D. et al. Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial. Lancet 395, 878–887 (2020).
US National Library of Medicine ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02315443 (2019).
Bach, A. et al. Modified peptides as potent inhibitors of the postsynaptic density-95/N-methyl-D-aspartate receptor interaction. J. Med. Chem. 51, 6450–6459 (2008).
Bach, A. et al. Design and synthesis of highly potent and plasma-stable dimeric inhibitors of the PSD-95-NMDA receptor interaction. Angew. Chem. Int. Ed. 48, 9685–9689 (2009).
Bach, A. et al. Selectivity, efficacy and toxicity studies of UCCB01-144, a dimeric neuroprotective PSD-95 inhibitor. Neuropharmacology 150, 100–111 (2019).
Nissen, K. B. et al. Targeting protein-protein interactions with trimeric ligands: high affinity inhibitors of the MAGUK protein family. PLoS ONE 10, e0117668 (2015).
Nissen, K. B., Andersen, J. J., Haugaard-Kedstrom, L. M., Bach, A. & Stromgaard, K. Design, synthesis, and characterization of fatty acid derivatives of a dimeric peptide-based postsynaptic density-95 (PSD-95) inhibitor. J. Med. Chem. 58, 1575–1580 (2015).
Bard, L. et al. Dynamic and specific interaction between synaptic NR2-NMDA receptor and PDZ proteins. Proc. Natl Acad. Sci. USA 107, 19561–19566 (2010).
Sainlos, M. et al. Biomimetic divalent ligands for the acute disruption of synaptic AMPAR stabilization. Nat. Chem. Biol. 7, 81–91 (2011).
Rogawski, M. A. Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Curr. 11, 56–63 (2011).
Zwart, R. et al. Perampanel, an antagonist of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors, for the treatment of epilepsy: studies in human epileptic brain and nonepileptic brain and in rodent models. J. Pharmacol. Exp. Ther. 351, 124–133 (2014).
Rueter, S. M., Burns, C. M., Coode, S. A., Mookherjee, P. & Emeson, R. B. Glutamate receptor RNA editing in vitro by enzymatic conversion of adenosine to inosine. Science 267, 1491–1494 (1995).
Sommer, B. et al. Flip and flop: a cell-specific functional switch in glutamate-operated channels of the CNS. Science 249, 1580–1585 (1990).
Kato, A. S. et al. New transmembrane AMPA receptor regulatory protein isoform, gamma-7, differentially regulates AMPA receptors. J. Neurosci. 27, 4969–4977 (2007).
Kato, A. S., Siuda, E. R., Nisenbaum, E. S. & Bredt, D. S. AMPA receptor subunit-specific regulation by a distinct family of type II TARPs. Neuron 59, 986–996 (2008).
Kott, S., Werner, M., Korber, C. & Hollmann, M. Electrophysiological properties of AMPA receptors are differentially modulated depending on the associated member of the TARP family. J. Neurosci. 27, 3780–3789 (2007).
Cho, C. H., St-Gelais, F., Zhang, W., Tomita, S. & Howe, J. R. Two families of TARP isoforms that have distinct effects on the kinetic properties of AMPA receptors and synaptic currents. Neuron 55, 890–904 (2007).
Ravula, S. et al. Lead optimization of 5-aryl benzimidazolone- and oxindole-based AMPA receptor modulators selective for TARP gamma-8. ACS Med. Chem. Lett. 9, 821–826 (2018).
Savall, B. M. et al. Discovery of imidazo[1,2-a]pyrazines and pyrazolo[1,5-c]pyrimidines as TARP gamma-8 selective AMPAR negative modulators. ACS Med. Chem. Lett. 10, 267–272 (2019).
Knopp, K. L. et al. Modulation of TARP gamma8-containing AMPA receptors as a novel therapeutic approach for chronic pain. J. Pharmacol. Exp. Ther. 369, 345–363 (2019).
Chen, S. et al. Activation and desensitization mechanism of AMPA receptor-TARP complex by cryo-EM. Cell 170, 1234–1246 (2017).
Lee, M. R. et al. Structural determinants of the gamma-8 TARP dependent AMPA receptor antagonist. ACS Chem. Neurosci. 8, 2631–2647 (2017).
von Engelhardt, J. et al. CKAMP44: a brain-specific protein attenuating short-term synaptic plasticity in the dentate gyrus. Science 327, 1518–1522 (2010).
Nakagawa, T. Structures of the AMPA receptor in complex with its auxiliary subunit cornichon. Science 366, 1259–1263 (2019).
Schwenk, J. & Fakler, B. Folding unpredicted. Science 366, 1194–1195 (2019).
Azumaya, C. M. et al. Screening for AMPA receptor auxiliary subunit specific modulators. PLoS ONE 12, e0174742 (2017).
Staudinger, J., Zhou, J., Burgess, R., Elledge, S. J. & Olson, E. N. PICK1: a perinuclear binding protein and substrate for protein kinase C isolated by the yeast two-hybrid system. J. Cell Biol. 128, 263–271 (1995).
Thul, P. J. & Lindskog, C. The human protein atlas: a spatial map of the human proteome. Protein Sci. 27, 233–244 (2018).
Jaafari, N., Henley, J. M. & Hanley, J. G. PICK1 mediates transient synaptic expression of GluA2-lacking AMPA receptors during glycine-induced AMPA receptor trafficking. J. Neurosci. 32, 11618–11630 (2012).
Xia, J., Zhang, X., Staudinger, J. & Huganir, R. L. Clustering of AMPA receptors by the synaptic PDZ domain-containing protein PICK1. Neuron 22, 179–187 (1999).
Jensen, K. L. et al. PICK1-deficient mice exhibit impaired response to cocaine and dysregulated dopamine homeostasis. eNeuro https://doi.org/10.1523/ENEURO.0422-17.2018 (2018).
Torres, G. E. The dopamine transporter proteome. J. Neurochem. 97, 3–10 (2006).
Torres, G. E. et al. Functional interaction between monoamine plasma membrane transporters and the synaptic PDZ domain-containing protein PICK1. Neuron 30, 121–134 (2001).
Li, Y. H., Zhang, N., Wang, Y. N., Shen, Y. & Wang, Y. Multiple faces of protein interacting with C kinase 1 (PICK1): Structure, function, and diseases. Neurochem. Int. 98, 115–121 (2016).
Thorsen, T. S. et al. A fluorescence polarization based screening assay for identification of small molecule inhibitors of the PICK1 PDZ domain. Comb. Chem. High. Throughput Screen. 14, 590–600 (2011).
Bach, A. et al. Structure-activity relationships of a small-molecule inhibitor of the PDZ domain of PICK1. Org. Biomol. Chem. 8, 4281–4288 (2010).
Thorsen, T. S. et al. Identification of a small-molecule inhibitor of the PICK1 PDZ domain that inhibits hippocampal LTP and LTD. Proc. Natl Acad. Sci. USA 107, 413–418 (2010).
Lin, E. Y. S. et al. Potent PDZ-domain PICK1 Inhibitors that modulate amyloid beta-mediated synaptic dysfunction. Sci. Rep. 8, 13438 (2018).
Marcotte, D. J. et al. Lock and chop: a novel method for the generation of a PICK1 PDZ domain and piperidine-based inhibitor co-crystal structure. Protein Sci. 27, 672–680 (2018).
Alfonso, S. et al. Synapto-depressive effects of amyloid beta require PICK1. Eur. J. Neurosci. 39, 1225–1233 (2014).
Daw, M. I. et al. PDZ proteins interacting with C-terminal GluR2/3 are involved in a PKC-dependent regulation of AMPA receptors at hippocampal synapses. Neuron 28, 873–886 (2000).
Famous, K. R. et al. Phosphorylation-dependent trafficking of GluR2-containing AMPA receptors in the nucleus accumbens plays a critical role in the reinstatement of cocaine seeking. J. Neurosci. 28, 11061–11070 (2008).
Garry, E. M. et al. Specific involvement in neuropathic pain of AMPA receptors and adapter proteins for the GluR2 subunit. Mol. Cell. Neurosci. 24, 10–22 (2003).
Rickhag, M. et al. Membrane-permeable C-terminal dopamine transporter peptides attenuate amphetamine-evoked dopamine release. J. Biol. Chem. 288, 27534–27544 (2013).
Christensen, N. R. et al. A high-affinity, bivalent PDZ domain inhibitor complexes PICK1 to alleviate neuropathic pain. EMBO Mol. Med. 12, e11248 (2020).
Schmid, C. L. et al. Bias factor and therapeutic window correlate to predict safer opioid analgesics. Cell 171, 1165–1175 (2017).
Campbell, A. P. & Smrcka, A. V. Targeting G protein-coupled receptor signalling by blocking G proteins. Nat. Rev. Drug Discov. 17, 789–803 (2018).
Amara, S. G., Jonas, V., Rosenfeld, M. G., Ong, E. S. & Evans, R. M. Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature 298, 240–244 (1982).
Goadsby, P. J., Edvinsson, L. & Ekman, R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann. Neurol. 28, 183–187 (1990).
Lassen, L. H. et al. CGRP may play a causative role in migraine. Cephalalgia 22, 54–61 (2002).
Hansen, J. M., Hauge, A. W., Olesen, J. & Ashina, M. Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia 30, 1179–1186 (2010).
Gonzalez-Hernandez, A., Marichal-Cancino, B. A., MaassenVanDenBrink, A. & Villalon, C. M. Side effects associated with current and prospective antimigraine pharmacotherapies. Expert. Opin. Drug Metab. Toxicol. 14, 25–41 (2018).
Burch, R. C., Loder, S., Loder, E. & Smitherman, T. A. The prevalence and burden of migraine and severe headache in the United States: updated statistics from government health surveillance studies. Headache 55, 21–34 (2015).
McLatchie, L. M. et al. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 393, 333–339 (1998).
Gingell, J. J., Hendrikse, E. R. & Hay, D. L. New insights into the regulation of CGRP-family receptors. Trends Pharmacol. Sci. 40, 71–83 (2019).
Hay, D. L. & Pioszak, A. A. Receptor activity-modifying proteins (RAMPs): new insights and roles. Annu. Rev. Pharmacol. Toxicol. 56, 469–487 (2016).
Shi, L. et al. Pharmacologic characterization of AMG 334, a potent and selective human monoclonal antibody against the calcitonin gene-related peptide receptor. J. Pharmacol. Exp. Ther. 356, 223–231 (2016). This study characterizes erenumab, the first mAb that targets the CALCRL–RAMP1 complex.
Evans, B. N., Rosenblatt, M. I., Mnayer, L. O., Oliver, K. R. & Dickerson, I. M. CGRP-RCP, a novel protein required for signal transduction at calcitonin gene-related peptide and adrenomedullin receptors. J. Biol. Chem. 275, 31438–31443 (2000).
Egea, S. C. & Dickerson, I. M. Direct interactions between calcitonin-like receptor (CLR) and CGRP-receptor component protein (RCP) regulate CGRP receptor signaling. Endocrinology 153, 1850–1860 (2012).
Dickerson, I. Role of CGRP-receptor component protein (RCP) in CLR/RAMP function. Curr. Protein Peptide Sci. 14, 407–415 (2013).
Liang, Y. L. et al. Cryo-EM structure of the active, Gs-protein complexed, human CGRP receptor. Nature 561, 492–497 (2018).
Schuster, N. M. & Rapoport, A. M. Calcitonin gene-related peptide-targeted therapies for migraine and cluster headache: a review. Clin. Neuropharmacol. 40, 169–174 (2017).
Goadsby, P. J. et al. A controlled trial of erenumab for episodic migraine. N. Engl. J. Med. 377, 2123–2132 (2017).
Tepper, S. J. Anti-calcitonin gene-related peptide (CGRP) therapies: update on a previous review after the American Headache Society 60th Scientific Meeting, San Francisco, June 2018. Headache 58, 276–290 (2018).
Tepper, S. J. History and review of anti-calcitonin gene-related peptide (CGRP) therapies: from translational research to treatment. Headache 58, 238–275 (2018).
Mullard, A. 2018 FDA drug approvals. Nat. Rev. Drug Discov. 18, 85–89 (2019).
Silberstein, S. D. et al. Fremanezumab for the preventive treatment of chronic migraine. N. Engl. J. Med. 377, 2113–2122 (2017).
Dodick, D. W. et al. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol. 13, 885–892 (2014).
Dodick, D. W. et al. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol. 13, 1100–1107 (2014).
US Food and Drug Administration. Vyepti: FDA-Approved Drugs https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761119 (2020).
Edvinsson, L. The trigeminovascular pathway: role of CGRP and CGRP receptors in migraine. Headache 57, 47–55 (2017).
Doods, H. et al. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br. J. Pharmacol. 129, 420–423 (2000).
Ho, T. W. et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 372, 2115–2123 (2008).
Voss, T. et al. A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. Cephalalgia 36, 887–898 (2016).
Negro, A. & Martelletti, P. Gepants for the treatment of migraine. Expert Opin. Investig. Drugs 28, 555–567 (2019).
US Food and Drug Administration. Ubrelvy: FDA-Approved Drugs https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211765 (2019).
Marcus, R. et al. BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia 34, 114–125 (2013).
US Food and Drug Administration Nurtec ODT: FDA-Approved Drugs https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212728 (2020).
Hay, D. L., Garelja, M. L., Poyner, D. R. & Walker, C. S. Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR review 25. Br. J. Pharmacol. 175, 3–17 (2018).
Bowery, N. G. GABAB receptor: a site of therapeutic benefit. Curr. Opin. Pharmacol. 6, 37–43 (2006).
Froestl, W. Chemistry and pharmacology of GABAB receptor ligands. Adv. Pharmacol. 58, 19–62 (2010).
Gassmann, M. & Bettler, B. Regulation of neuronal GABAB receptor functions by subunit composition. Nat. Rev. Neurosci. 13, 380–394 (2012).
Turecek, R. et al. Auxiliary GABAB receptor subunits uncouple G protein βγ subunits from effector channels to induce desensitization. Neuron 82, 1032–1044 (2014).
Bettler, B. & Fakler, B. Ionotropic AMPA-type glutamate and metabotropic GABAB receptors: determining cellular physiology by proteomes. Curr. Opin. Neurobiol. 45, 16–23 (2017).
Zheng, S., Abreu, N., Levitz, J. & Kruse, A. C. Structural basis for KCTD-mediated rapid desensitization of GABAB signalling. Nature 567, 127–131 (2019).
Zuo, H. et al. Structural basis for auxiliary subunit KCTD16 regulation of the GABAB receptor. Proc. Natl Acad. Sci. USA 116, 8370–8379 (2019).
Metz, M., Gassmann, M., Fakler, B., Schaeren-Wiemers, N. & Bettler, B. Distribution of the auxiliary GABAB receptor subunits KCTD8, 12, 12b, and 16 in the mouse brain. J. Comp. Neurol. 519, 1435–1454 (2011).
Fritzius, T. & Bettler, B. The organizing principle of GABAB receptor complexes: Physiological and pharmacological implications. Basic Clin. Pharmacol. Toxicol. https://doi.org/10.1111/bcpt.13241 (2019).
Sibille, E. et al. A molecular signature of depression in the amygdala. Am. J. Psychiatry 166, 1011–1024 (2009).
Lee, M. T. et al. Genome-wide association study of bipolar I disorder in the Han Chinese population. Mol. Psychiatry 16, 548–556 (2011).
Booker, S. A. et al. KCTD12 auxiliary proteins modulate kinetics of GABAB receptor-mediated inhibition in cholecystokinin-containing interneurons. Cereb. Cortex 27, 2318–2334 (2017).
Cathomas, F. et al. Altered emotionality and neuronal excitability in mice lacking KCTD12, an auxiliary subunit of GABAB receptors associated with mood disorders. Transl. Psychiatry 5, e510 (2015).
Sereikaite, V. et al. Targeting the gamma-aminobutyric acid type B (GABAB) receptor complex: development of inhibitors targeting the K+ channel tetramerization domain (KCTD) containing proteins/GABAB receptor protein-protein interaction. J. Med. Chem. 62, 8819–8830 (2019). This article reports the first tool compound that binds to auxiliary KCTD subunits of GABAB receptors.
Rice, H. C. et al. Secreted amyloid-beta precursor protein functions as a GABABR1a ligand to modulate synaptic transmission. Science 363, eaao4827 (2019).
Dinamarca, M. C. et al. Complex formation of APP with GABAB receptors links axonal trafficking to amyloidogenic processing. Nat. Commun. 10, 1331 (2019).
Rouault, A. A. J., Srinivasan, D. K., Yin, T. C., Lee, A. A. & Sebag, J. A. Melanocortin receptor accessory proteins (MRAPs): Functions in the melanocortin system and beyond. Biochim. Biophys. Acta Mol. Basis Dis. 1863, 2462–2467 (2017).
Baron, M. et al. Loss-of-function mutations in MRAP2 are pathogenic in hyperphagic obesity with hyperglycemia and hypertension. Nat. Med. 25, 1733–1738 (2019).
Andrei, S. A. et al. Stabilization of protein-protein interactions in drug discovery. Expert Opin. Drug Discov. 12, 925–940 (2017).
Arkin, M. R., Tang, Y. & Wells, J. A. Small-molecule inhibitors of protein-protein interactions: progressing toward the reality. Chem. Biol. 21, 1102–1114 (2014).
Manglik, A., Kobilka, B. K. & Steyaert, J. Nanobodies to study G protein-coupled receptor structure and function. Annu. Rev. Pharmacol. Toxicol. 57, 19–37 (2017).
Burslem, G. M. et al. The advantages of targeted protein degradation over inhibition: an RTK case study. Cell Chem. Biol. 25, 67–77 (2018).
Bensimon, A. et al. Targeted degradation of SLC transporters reveals amenability of multi-pass transmembrane proteins to ligand-induced proteolysis. Cell Chem. Biol. 27, 728–739 (2020).
Field, M. J. et al. Identification of the alpha2-delta-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. Proc. Natl Acad. Sci. USA 103, 17537–17542 (2006).
Modell, A. E., Blosser, S. L. & Arora, P. S. Systematic targeting of protein-protein interactions. Trends Pharmacol. Sci. 37, 702–713 (2016).
Wasko, M. J., Pellegrene, K. A., Madura, J. D. & Surratt, C. K. A role for fragment-based drug design in developing novel lead compounds for central nervous system targets. Front. Neurol. 6, 197 (2015).
Hillier, B. J. Unexpected modes of PDZ domain scaffolding revealed by structure of nNOS-syntrophin complex. Science 284, 812–815 (1999).
M.I.R. is a full-time employee of Novo Nordisk at the time of publication. K.S. is a co-founder and a part-time employee of Avilex Pharma. B.B. is a member of the scientific advisory board of Addex Therapeutics, Geneva. L.S.C. is a full-time employee of BioInnovation Institute. D.S.B. is a full-time employee of Janssen Pharmaceuticals.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- Blood–brain barrier
The blood–brain barrier strictly restricts which molecules can enter the brain, and it comprises tight junctions between endothelial cells, astrocytic endfeet and a basement membrane.
- Scaffolding protein
A protein that organizes multiple proteins into a functional protein complex.
A mechanism that uncouples downstream receptor signalling during prolonged activation to attenuate the excessive cellular effects.
- Phenotypic drug discovery
A screening method to identify compounds with desired biological phenotypes that is agnostic of the molecular target.
- DNA-encoded chemical libraries
(DELs). Large collections of small molecules (up to 109) whose structure is connected to a unique DNA sequence, allowing pooled screening. Sequencing of screening hits subsequently allows chemical identification.
- Targeted protein degradation
A technology that targets a protein of interest for degradation by using the cellular degradation machinery, such as the ubiquitin–proteasome system.
- Cell-penetrating peptides
Short peptide sequences that promote the cellular uptake of various cargoes, such as peptides, proteins and oligonucleotides.
A process in which neurons are damaged owing to excessive activation of glutamate receptors.
- Functional proteomics
A proteomic approach that aims to elucidate and identify interacting proteins of stable protein complexes.
- Biased signalling
A concept of receptor modulation that allows selective pharmacological activation of one downstream signalling pathway over others.
- Nootropic effects
A general term that describes improved cognitive functions.
About this article
Cite this article
Rosenbaum, M.I., Clemmensen, L.S., Bredt, D.S. et al. Targeting receptor complexes: a new dimension in drug discovery. Nat Rev Drug Discov 19, 884–901 (2020). https://doi.org/10.1038/s41573-020-0086-4